^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YH001

    i
    Other names: YH001, YH-001
    Associations

    News

    Trials
    Company:
    Biocytogen, Tracon Pharma
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (clinicaltrials.gov)
    P2, N=0, Withdrawn, Eucure (Beijing) Biopharma Co., Ltd | N=80 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • YH001
    over1year
    A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Eucure (Beijing) Biopharma Co., Ltd | Trial completion date: Jun 2023 --> Mar 2025 | Initiation date: Dec 2022 --> Jun 2023 | Trial primary completion date: Dec 2022 --> Dec 2024
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • YH001
    almost2years
    A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Eucure (Beijing) Biopharma Co., Ltd | Initiation date: Mar 2022 --> Dec 2022
    Trial initiation date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • YH001
    over2years
    A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Eucure (Beijing) Biopharma Co., Ltd
    New P2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • YH001
    almost4years
    [VIRTUAL] A novel anti-CTLA-4 antibody with potent anti-tumor activity emerged using humanized CTLA-4 mouse model (AACR-II 2020)
    Ipilimumab, a fully human IgG1 monoclonal antibody, is the only commercially available CTLA-4 antagonist. YH001 showed dose-dependent in vivo anti-cancer efficacy, as well as Treg depletion and increased CD8+/Treg ratio in human CTLA-4 knock-in mice bearing MC38 tumors.Exposure to YH001 was dose proportional with a half-life of approximately 5 days in cynomolgus monkey. Our preclinical investigation of YH001 demonstrates Biocytogen’s capability in discovering clinical candidates using its robust antibody discovery platform.
    Preclinical • IO biomarker
    |
    IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    CTLA4 expression
    |
    Yervoy (ipilimumab) • YH001